REG - Proteome Sciences - Expansion into the US

Proteome SciencesAnnouncement

12/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230512:nRSL1789Za&default-theme=true

RNS Number : 1789Z  Proteome Sciences PLC  12 May 2023

12 May 2023

 

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Proteome Sciences expands into the US: New Facility to open in San Diego

 

Proteome Sciences plc is pleased to announce the expansion of its proteomics
services into the United States of America ("US"). A state of the art facility
will be based in San Diego, California, to provide easy access to the
established and growing pharmaceutical and biotechnology proteomics services
requirements across the US and, in particular, the research hubs on the west
coast. The Company's  subsidiary, Proteome Sciences US Inc, has commenced
staff recruitment and the new facility is expected to be fully operational in
the fourth quarter of 2023.

 

Commenting on the new laboratory, Dr. Ian Pike, Chief Scientific Officer and
President of Proteome Sciences US Inc. said "This is a major development for
Proteome Sciences, building on the strong foundations of our services business
in Europe. Whilst we already have an excellent customer base in the US,
concerns over shipping costs, timing delays and customs delays have restricted
the volume of orders that could be processed. We will now be able to provide a
more accessible service to the rapidly growing pharma/biotech community across
the US as the demand for proteomics services continues to expand."

 

Dr. Mariola Söhngen, Chief Executive Officer of Proteome Sciences plc, added
"Internationalisation is a key element of our growth strategy. With a major
part of our service and reagent business already focused over there, it is a
logical step to establish our own facility for customers in the US. This is a
real milestone for Proteome Sciences and we are looking forward to improving
our service to the US marketplace with the San Diego facility opening later
this year. "

 

 

For further information:

 Proteome Sciences plc
 Dr. Mariola Soehngen, Chief Executive Officer                           Tel: +44 (0)20 7043 2116

 Dr. Ian Pike, Chief Scientific Officer
 Richard Dennis, Chief Commercial Officer

 Abdelghani Omari, Chief Financial Officer

 Allenby Capital Limited (Nominated Adviser & Broker)
 John Depasquale / Jeremy Porter (Corporate Finance)                     Tel: +44 (0) 20 3328 5656

 Tony Quirke / Stefano Aquilino (Equity Sales & Corporate Broking)

 

About Proteome Sciences plc. (www.proteomics.com (http://www.proteomics.com/)
)

 

Proteome Sciences plc is a specialist provider of contract proteomics services
to enable drug discovery, development and biomarker identification, and
employs proprietary workflows for the optimum analysis of tissues, cells and
body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and
contextualising new targets and defining mechanisms of biological activity,
while analysis using Super-Depletion and TMTcalibrator™ provides access to
over 8,500 circulating plasma proteins for the discovery of disease-related
biomarkers. Targeted assay development using mass spectrometry delivers high
sensitivity, interference-free biomarker analyses in situations where standard
ELISA assays are not available.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPUPWAUPWPUG